Literature DB >> 24495728

[Expression of Prion protein and its clinical significance in oral squamous cells carcinoma and oral leukoplakia].

Jie Zhang1, Yan Zeng, Jun Zheng, Jiang Xu2.   

Abstract

OBJECTIVE: To examine Prion protein(PrP) expression and its clinical significance in oral mucosa, oral leukoplakia, oral squamous cell carcinoma(OSCC) and its subgroups.
METHODS: Expression of PrP in OSCC, oral leukoplakia and mucosa specimen was detected by immunohistochemistry. The association between the expression and gender, TNM clinical stages, pathological grades was evaluated.
RESULTS: The positive expression rate of PrP in normal, oral leukoplakia and OSCC tissues was 15% (3/20) , 42% (11/26) and 95% (80/84) , respectively. There was a significant difference between the expression of PrP in leukoplakia and in high, moderately and poorly differentiated OSCC(P < 0.05). The positive expression rate was increased with the declining of pathological differentiation (P < 0.05). There was no significant difference in PrP expression among lymph node metastasis and gender. PrP expression of stages I and II was up-regulated with the decreased differentiation (P < 0.05). There was no significant difference in PrP expression between stage III and IV (P > 0.05). Between stages I+II and III+IV in the overa II expression of PrP, there was a significant difference(P < 0.05).
CONCLUSIONS: The high expression of PrP in OSCC and the progressive expression from leukoplakia to OSCC was closely related to the carcinogenesis of OSCC, pathologic stage and clinical TNM stage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24495728

Source DB:  PubMed          Journal:  Zhonghua Kou Qiang Yi Xue Za Zhi        ISSN: 1002-0098


  1 in total

1.  A panel of monoclonal antibodies against the prion protein proves that there is no prion protein in human pancreatic ductal epithelial cells.

Authors:  Liheng Yang; Yan Zhang; Lipeng Hu; Ying Zhu; Man-Sun Sy; Chaoyang Li
Journal:  Virol Sin       Date:  2014-08-14       Impact factor: 4.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.